Vesicular Stomatitis Virus Expressing Tumor Suppressor p53 Is a Highly Attenuated, Potent Oncolytic Agent

Por Heiber, Joshua F., Barber, Glen N.
Publicado em 2011

Context and location dependence of adaptive Foxp3(+) regulatory T cell formation during immunopathological conditions

Por Heiber, Joshua F., Geiger, Terrence L.
Publicado em 2012

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer

Por Heiber, Joshua F., Xu, Xiang-Xi, Barber, Glen N.
Publicado em 2011

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

Por O’Hear, Carol, Heiber, Joshua F., Schubert, Ingo, Fey, Georg, Geiger, Terrence L.
Publicado no Haematologica (2015)

The Alpha Subunit of Eukaryotic Initiation Factor 2B (eIF2B) Is Required for eIF2-Mediated Translational Suppression of Vesicular Stomatitis Virus

Por Elsby, Rachel, Heiber, Joshua F., Reid, Peter, Kimball, Scot R., Pavitt, Graham D., Barber, Glen N.
Publicado em 2011

Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models

Por Capo-chichi, Callinice D., Yeasky, Toni M., Heiber, Joshua F., Wang, Ying, Barber, Glen N., Xu, Xiang-Xi
Publicado em 2009

Vesicular stomatitis virus inhibits mitotic progression and triggers cell death

Por Chakraborty, Papia, Seemann, Joachim, Mishra, Ram K, Wei, Jen-Hsuan, Weil, Lauren, Nussenzveig, Daniel R, Heiber, Joshua, Barber, Glen N, Dasso, Mary, Fontoura, Beatriz M A
Publicado em 2009

PRECLINICAL SAFETY AND ACTIVITY OF RECOMBINANT VSV-IFN-B IN AN IMMUNOCOMPETENT MODEL OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Por Kurisetty, Vittal VS, Heiber, Joshua, Myers, Rae, Pereira, Guilherme S., Goodwin, Jarrard W., Federspiel, Mark J., Russell, Stephen J., Peng, Kah Whye, Barber, Glen, Merchan, Jaime R.
Publicado em 2014